DDInter1729 DDInter1828
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class that is marketed by Merck under the brand name Clinoril. Like other NSAIDs, it may be used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted _in vivo_ to an active sulfide compound by liver enzymes. There is evidence from some studies that sulindac may be associated with fewer gastrointestinal side effects than other NSAIDs, except for the cyclooxygenase-2 (COX-2) inhibitor drug class. This may be due to the sulfide metabolite undergoing enterohepatic circulation thus maintaining constant blood levels of the compound without inducing gastrointestinal effects, where the drug is excreted in the bile and then reabsorbed from the intestines. While its full mechanism of action is not fully understood, sulindac
Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Tolbutamide appears to be metabolized in the liver. Tolbutamide and its metabolites are excreted in urine (75-85%) and feces.
Sulindac {u} (Compound) binds {v} (Gene) SLC22A6
SLC22A6 {u} (Gene) is bound by {v} (Compound) Tolbutamide
Sulindac {u} (Compound) causes {v} (Side Effect) Photosensitivity reaction
Photosensitivity reaction {u} (Side Effect) is caused by {v} (Compound) Tolbutamide
Sulindac {u} (Compound) binds {v} (Gene) SLC22A6
SLC22A6 {u} (Gene) is bound by {v} (Compound) Probenecid
Probenecid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolbutamide
Sulindac {u} (Compound) causes {v} (Side Effect) Photosensitivity reaction
Photosensitivity reaction {u} (Side Effect) is caused by {v} (Compound) Tolazamide
Tolazamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Sulindac {u} (Compound) binds {v} (Gene) SLC22A6
SLC22A6 {u} (Gene) is bound by {v} (Compound) Chlorpropamide
Chlorpropamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Sulindac {u} (Compound) causes {v} (Side Effect) Photosensitivity reaction
Photosensitivity reaction {u} (Side Effect) is caused by {v} (Compound) Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Tolbutamide
Sulindac {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is associated with {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is treated by {v} (Compound) Tolbutamide
Sulindac {u} (Compound) binds {v} (Gene) SLC22A6
SLC22A6 {u} (Gene) is bound by {v} (Compound) Valproic acid
Valproic acid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tolbutamide
Sulindac {u} (Compound) causes {v} (Side Effect) Urticaria
Urticaria {u} (Side Effect) is caused by {v} (Compound) Probenecid
Probenecid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolbutamide
Sulindac {u} (Compound) binds {v} (Gene) AKR1B1
AKR1B1 {u} (Gene) regulates {v} (Gene) SUV39H1
SUV39H1 {u} (Gene) is upregulated by {v} (Compound) Tolbutamide
Sulindac (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Tolbutamide (Compound)
Sulindac (Compound) causes Photosensitivity reaction (Side Effect) and Photosensitivity reaction (Side Effect) is caused by Tolbutamide (Compound)
Sulindac (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Probenecid (Compound) and Probenecid may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Sulindac (Compound) causes Photosensitivity reaction (Side Effect) and Photosensitivity reaction (Side Effect) is caused by Tolazamide (Compound) and Tolazamide (Compound) resembles Tolbutamide (Compound)
Sulindac (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Chlorpropamide (Compound) and Chlorpropamide (Compound) resembles Tolbutamide (Compound)
Sulindac (Compound) causes Photosensitivity reaction (Side Effect) and Photosensitivity reaction (Side Effect) is caused by Glipizide (Compound) and Glipizide (Compound) resembles Tolbutamide (Compound)
Sulindac (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is associated with type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Tolbutamide (Compound)
Sulindac (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Valproic acid (Compound) and Valproic acid may cause a minor interaction that can limit clinical effects when taken with Tolbutamide
Sulindac (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Probenecid (Compound) and Probenecid may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Sulindac (Compound) binds AKR1B1 (Gene) and AKR1B1 (Gene) regulates SUV39H1 (Gene) and SUV39H1 (Gene) is upregulated by Tolbutamide (Compound)